JPWO2021069705A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021069705A5 JPWO2021069705A5 JP2022521718A JP2022521718A JPWO2021069705A5 JP WO2021069705 A5 JPWO2021069705 A5 JP WO2021069705A5 JP 2022521718 A JP2022521718 A JP 2022521718A JP 2022521718 A JP2022521718 A JP 2022521718A JP WO2021069705 A5 JPWO2021069705 A5 JP WO2021069705A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- branched
- membered
- pharmaceutically acceptable
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH12812019 | 2019-10-09 | ||
| CH01281/19 | 2019-10-09 | ||
| PCT/EP2020/078483 WO2021069705A1 (en) | 2019-10-09 | 2020-10-09 | Isoindolinone compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022551185A JP2022551185A (ja) | 2022-12-07 |
| JP2022551185A5 JP2022551185A5 (https=) | 2023-10-17 |
| JPWO2021069705A5 true JPWO2021069705A5 (https=) | 2023-10-17 |
| JP7724394B2 JP7724394B2 (ja) | 2025-08-18 |
Family
ID=68242216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521718A Active JP7724394B2 (ja) | 2019-10-09 | 2020-10-09 | イソインドリノン化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220242846A1 (https=) |
| EP (1) | EP4041231A1 (https=) |
| JP (1) | JP7724394B2 (https=) |
| WO (1) | WO2021069705A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023507590A (ja) * | 2019-12-17 | 2023-02-24 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| CN116583509A (zh) * | 2020-10-07 | 2023-08-11 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| JP2024504932A (ja) * | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| WO2022153220A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Methods for the identification of degrons |
| CN117242060A (zh) * | 2021-01-13 | 2023-12-15 | 蒙特罗萨医疗公司 | 异吲哚啉酮化合物 |
| EP4278014A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Treatment of myc-driven cancers with gspt1 degraders |
| WO2022200857A1 (en) * | 2021-03-22 | 2022-09-29 | Monte Rosa Therapeutics Ag | Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons |
| WO2022256623A1 (en) | 2021-06-04 | 2022-12-08 | Monte Rosa Therapeutics, Inc. | E3 ligase fusion proteins for proximity detection |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023001028A1 (zh) * | 2021-07-19 | 2023-01-26 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
| WO2023069708A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and uses thereof |
| WO2023069700A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069720A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023091567A1 (en) | 2021-11-17 | 2023-05-25 | Monte Rosa Therapeutics, Inc. | Degron and neosubstrate identification |
| WO2023201282A1 (en) * | 2022-04-14 | 2023-10-19 | Bristol-Myers Squibb Company | Novel gspt1 compounds and methods of use of the novel compounds |
| WO2024015855A1 (en) | 2022-07-13 | 2024-01-18 | Monte Rosa Therapeutics, Inc. | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS |
| CN119630648A (zh) * | 2022-07-14 | 2025-03-14 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮衍生物的制备方法及其晶形 |
| WO2024027795A1 (zh) * | 2022-08-04 | 2024-02-08 | 苏州开拓药业股份有限公司 | 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| CN120303264A (zh) | 2022-09-09 | 2025-07-11 | 医诺康治疗公司 | CK1α和双重CK1α/GSPT1降解化合物 |
| WO2024201248A1 (en) * | 2023-03-24 | 2024-10-03 | Pin Therapeutics, Inc. | Compounds and methods for degrading gspt1 |
| CN121311477A (zh) * | 2023-09-06 | 2026-01-09 | 上海超阳药业有限公司 | 内酰胺类衍生物及其应用 |
| WO2025085416A1 (en) * | 2023-10-16 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1 compounds and methods of use of the compounds |
| WO2025146112A1 (en) * | 2024-01-05 | 2025-07-10 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Gspt1 degrading compounds and compositions and uses thereof |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
| WO2025259615A1 (en) * | 2024-06-11 | 2025-12-18 | Triana Biomedicines, Inc. | Modulators of cdk2 and uses thereof |
| WO2026007898A1 (zh) * | 2024-07-01 | 2026-01-08 | 上海海雁医药科技有限公司 | 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| MX2009001989A (es) * | 2006-08-30 | 2009-03-09 | Celgene Corp | Compuestos de isoindolina 5-substituidos. |
| PE20110547A1 (es) | 2008-10-29 | 2011-08-04 | Celgene Corp | Compuestos de isoindolina con actividad anticancerigena |
| TWI696615B (zh) | 2016-05-05 | 2020-06-21 | 瑞士商伊蘭科動物健康公司 | 雜芳基-1,2,4-三唑及雜芳基-三唑化合物 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11220515B2 (en) * | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| BR112022019532A2 (pt) * | 2020-03-31 | 2022-12-06 | Orum Therapeutics Inc | Conjugados de neodegrader |
-
2020
- 2020-10-09 EP EP20789952.7A patent/EP4041231A1/en active Pending
- 2020-10-09 WO PCT/EP2020/078483 patent/WO2021069705A1/en not_active Ceased
- 2020-10-09 JP JP2022521718A patent/JP7724394B2/ja active Active
-
2022
- 2022-04-08 US US17/716,169 patent/US20220242846A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021069705A5 (https=) | ||
| JP2021169499A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| JP2020169171A5 (https=) | ||
| JP2001526269A5 (https=) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| RU2020115095A (ru) | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 | |
| KR920009796A (ko) | 3-아미도인돌릴 유도체 | |
| CA2679232A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
| JP2021514001A5 (https=) | ||
| JPWO2019213318A5 (https=) | ||
| JP2006501181A5 (https=) | ||
| JP2014015465A5 (https=) | ||
| RU2013130250A (ru) | Замещенные пуриновые и 7-деазапуриновые соединения | |
| JP2005526857A5 (https=) | ||
| JP2019500315A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| RU2010112450A (ru) | Производные хиназолинона, полезные в качестве ванилоидных антагонистов | |
| JP2021046404A5 (https=) | ||
| JP2011509302A5 (https=) | ||
| JPWO2022152821A5 (https=) | ||
| JP2019528279A5 (https=) | ||
| JPWO2020023560A5 (https=) | ||
| JPWO2019165358A5 (https=) | ||
| JP2019533007A5 (https=) |